Latest Clinical Development News

Argent BioPharma reports significant operational savings through manufacturing outsourcing, encouraging Phase IIb results for CimetrA®, and key regulatory approvals for cannabinoid therapies in Germany.

Patrys Limited advances its PAT-DX3 therapy development for inflammatory diseases while navigating cash flow challenges and pursuing partnerships to sustain operations.

Starpharma reports steady progress in its DEP® drug development programs, launches new marketing campaigns in key regions, and maintains a strong cash position of $17.2 million as it refines clinical strategies and partnerships.

Alterity Therapeutics reports compelling Phase 2 clinical trial results for ATH434 in Multiple System Atrophy, alongside a significant capital raise strengthening its financial position for upcoming regulatory milestones.

Microba Life Sciences reports robust growth in microbiome diagnostic testing across Australia and the UK, while advancing US market entry plans and transitioning its Therapeutics business to a partnering model.

Noxopharm Limited has successfully cleared key preclinical hurdles for its SOF-SKN™ lupus drug and expanded its Sofra™ platform collaborations, supported by fresh funding to propel upcoming clinical trials.

Opthea Limited has discontinued its wet AMD development program following Phase III trial failures, slashing its workforce by 65% amid ongoing financial uncertainty and negotiations with investors.

Island Pharmaceuticals has completed dosing in the Phase 2b cohort of its dengue fever trial, with pharmacokinetic targets met and top-line results expected next month. The company also strengthened its balance sheet by raising $1.94 million through option exercises.

Tryptamine Therapeutics has secured a landmark agreement with Swinburne University to initiate the first clinical trial of its IV-infused psilocin formulation TRP-8803 for Binge Eating Disorder, aiming to build on promising Phase 2a data.

Ecofibre Limited reported a $2.2 million operating cash outflow in 3Q25 with total cash at $1.3 million, highlighting mixed progress across its business units and a pressing need to monetise assets to sustain operations.

Paradigm Biopharmaceuticals has secured ethics approval and appointed a CRO to launch its global phase 3 trial for injectable Pentosan Polysulfate Sodium in knee osteoarthritis, while initiating a substantial capital raising program.

Zelira Therapeutics has enhanced its financial flexibility through a $1.15 million R&D tax refund and a $1 million At-the-Market equity facility, while progressing FDA trial preparations for its HOPE® 1 autism treatment.